KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Financing Activities: 2017-2024

Historic Cash from Financing Activities for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $83.6 million.

  • Aquestive Therapeutics' Cash from Financing Activities rose 478988.24% to $81.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.1 million, marking a year-over-year increase of 16.90%. This contributed to the annual value of $83.6 million for FY2024, which is 2003.47% up from last year.
  • Aquestive Therapeutics' Cash from Financing Activities amounted to $83.6 million in FY2024, which was up 2,003.47% from $4.0 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Cash from Financing Activities high stood at $83.6 million for FY2024, and its period low was $4.0 million during FY2023.
  • For the 3-year period, Aquestive Therapeutics' Cash from Financing Activities averaged around $33.1 million, with its median value being $11.6 million (2022).
  • Per our database at Business Quant, Aquestive Therapeutics' Cash from Financing Activities crashed by 65.72% in 2023 and then surged by 2,003.47% in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Cash from Financing Activities stood at $28.5 million in 2020, then grew by 5.81% to $30.1 million in 2021, then plummeted by 61.50% to $11.6 million in 2022, then slumped by 65.72% to $4.0 million in 2023, then skyrocketed by 2,003.47% to $83.6 million in 2024.